<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04330781</url>
  </required_header>
  <id_info>
    <org_study_id>2019-38</org_study_id>
    <nct_id>NCT04330781</nct_id>
  </id_info>
  <brief_title>Radiotherapy of Head and Neck Cancer Using an Intraoral Stent</brief_title>
  <official_title>Patient-reported Outcome After Radiotherapy of Oral Cavity and Sinonasal Cancer Using an Intraoral Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo Metropolitan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiotherapy of oral cavity cancer and sinonasal cancer is associated with acute and late
      morbidity. Use of an intraoral stent will provide a larger distance between the tongue and
      palate and can reduce side-effects. The aim of the present study is to confirm that an
      intraoral stent is not a significant bother to the patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have previously performed a pilot study on the feasibility of the intraoral
      stent in patients receiving radiotherapy for tongue cancer. It was found that most of the
      patients tolerated the stent. The mean radiation dose to the hard palate was reduced by 61%
      (absolute percentage) as compared with a control group not using the stent. Based on these
      results, the investigators wish to perform a study on a larger cohort to confirm that the
      intraoral stent will not lead to increased symptoms towards the end of the radiotherapy
      period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-reported outcome</measure>
    <time_frame>At the end of radiotherapy (5-6 weeks)</time_frame>
    <description>Less than 10% change (non-inferiority) in sum of pain scores (no 31-34) in questionnaire European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - H&amp;N 35 plus 3 extra questions regarding pain in the palate, tongue and lips</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Oral Cavity Cancer</condition>
  <condition>Sinonasal Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N=123</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N=31</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intraoral stent</intervention_name>
    <description>Radiotherapy with intraoral stent</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intraoral stent</intervention_name>
    <description>Radiotherapy without intraoral stent</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Radiation dose 30 Gy or higher

          -  Cancer in the inferior part of the oral cavity (e.g. tongue or floor of mouth cancer)
             or superior part of the oral cavity (e.g. hard palate) or sinonasal cancer

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-3

          -  Ability to understand and answer questionnaire

        Exclusion Criteria:

          -  Radiotherapy target both in the superior part of the oral cavity and elective neck
             level I
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Einar Dale, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Consultant</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Einar Dale, MD PhD</last_name>
    <phone>+4722934000</phone>
    <email>eindal@ous-hf.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Einar Dale, MD PhD</last_name>
      <phone>+4722934000</phone>
      <email>eindal@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Berit Bø, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Torbjørn Furre, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Einar Dale</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Intraoral stent</keyword>
  <keyword>Head and neck cancer</keyword>
  <keyword>Patient-reported outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

